XML 93 R55.htm IDEA: XBRL DOCUMENT v3.7.0.1
- Condensed Consolidated Statement of Cash Flow (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended 12 Months Ended
Dec. 31, 2016
Oct. 01, 2016
 [2]
Jul. 02, 2016
 [3]
Apr. 02, 2016
Dec. 31, 2015
Sep. 26, 2015
Jun. 27, 2015
Mar. 28, 2015
Dec. 27, 2014
Sep. 27, 2014
Dec. 31, 2015
Dec. 27, 2014
Dec. 31, 2016
Jun. 27, 2015
Jun. 28, 2014
Cash Flows From (For) Operating Activities                              
Net income $ (1,359.1) [1] $ (1,590.2) $ (534.3) $ (529.2) [4] $ (218.4) [5] $ 260.9 [6] $ (22.2) [7] $ (22.2) [8] $ 151.1 [9] $ 29.4 $ 42.5 $ 180.6 $ (4,012.8) $ 136.1 $ 232.8
Adjustments to derive cash flows                              
Total loss on extinguishment of debt                 9.6   0.9 9.6 1.1 10.5 165.8
Restructuring charges         24.7           26.9 4.2 31.0 5.1 47.0
Depreciation and amortization                     182.4   457.0 258.7 206.1
Impairment charges (credits)                     215.6 0.0 2,631.0 6.8 6.0
Tysabri® royalty stream - change in fair value (1,115.6) [1] $ 377.4 $ 910.8 204.4 [4] (116.6) [5] (173.8) [6] 69.2 [7] (100.8) [8] 105.8 [9] (58.9) (57.3) (46.9) 2,608.2 (78.5) (26.6)
Share-based compensation                     22.8   23.0 31.6 24.6
Loss on acquisition-related foreign currency derivatives               $ 258.2 $ 64.7   0.0   0.0 326.4 0.0
Deferred income taxes                     (120.0)   (990.9) (16.3) (49.7)
Amortization of financing fees and debt discount (premium)                     (10.2)   (24.7) 0.2 2.0
Other non-cash adjustments                     18.1   33.5 10.2 4.5
Subtotal                     321.7   756.4 690.8 612.5
Increase (decrease) in cash due to:                              
Accounts receivable                     52.5   (0.6) (51.1) (140.5)
Inventories                     (29.6)   100.7 (11.4) 84.7
Accounts payable                     (194.1)   (75.7) 120.5 (24.9)
Payroll and related taxes                     (38.2)   (41.1) (30.2) (55.5)
Accrued customer programs                     34.4   (13.9) 71.3 113.1
Accrued liabilities                     108.1   (79.5) 42.8 23.0
Accrued income taxes                     (56.8)   20.9 21.9 (11.3)
Other                     2.9   (12.3) 0.6 31.9
Subtotal                     (120.8)   (101.5) 164.4 20.5
Net cash from (for) operating activities                     200.9   654.9 855.2 633.0
Cash Flows From (For) Investing Activities                              
Proceeds from royalty rights                     166.3   353.7 344.6 60.5
Acquisitions of businesses, net of cash acquired                     (791.6)   (427.4) (2,177.8) (1,605.8)
Asset acquisitions                     0.0   (65.1) (4.0) 0.0
Settlement of acquisition-related foreign currency derivatives                     (1.3)   0.0 (329.9) 0.0
Proceeds from sale of securities                     0.0   4.5 0.0 81.4
Additions to property and equipment                     (77.8)   (106.2) (137.0) (171.6)
Other investing                     (3.7)   (3.6) 1.8 (8.8)
Net cash from (for) investing activities                     (708.1)   (175.0) (2,302.3) (1,644.3)
Cash Flows From (For) Financing Activities                              
Issuances of long-term debt                     0.0   1,190.3 2,504.3 3,293.6
Borrowings (repayments) of revolving credit agreements and other financing, net                     718.0   (802.5) (54.0) (3.0)
Payments on long-term debt                     (28.3)   (559.2) (1,823.5) (2,035.0)
Deferred financing fees                     (0.3)   (2.8) (28.1) (48.8)
Premium on early debt retirement                     0.0   (0.6) 0.0 (133.5)
Equity issuance costs                     0.0   (10.3) (35.7) 0.0
Issuance of ordinary shares                     4.9   8.3 1,043.5 9.8
Repurchase of ordinary shares                     (500.0)   0.0 0.0 0.0
Cash dividends                     (36.3)   (83.2) (64.8) (46.1)
Purchase of noncontrolling interest                           0.0  
Other financing                     (8.4)   (8.7) (19.3) (9.0)
Net cash from (for) financing activities                     149.6   (268.7) 1,522.4 1,028.0
Effect of exchange rate changes on cash and cash equivalents                     (10.2)   (6.7) (89.2) 2.9
Net increase (decrease) in cash and cash equivalents                     (367.8)   204.5 (13.9) 19.6
Cash and cash equivalents, beginning of period       417.8   785.6       799.5 785.6 799.5 417.8 799.5 779.9
Cash and cash equivalents, end of period $ 622.3       417.8   785.6       417.8   622.3 785.6 799.5
Previously Reported                              
Cash Flows From (For) Operating Activities                              
Net income                     5.6     128.0 205.3
Adjustments to derive cash flows                              
Total loss on extinguishment of debt                     0.9     10.5 165.8
Restructuring charges                     26.9     5.1 47.0
Depreciation and amortization                     328.0     548.8 358.9
Impairment charges (credits)                     215.6     0.0 0.0
Tysabri® royalty stream - change in fair value                     0.0     0.0 0.0
Share-based compensation                     24.8     31.6 24.6
Loss on acquisition-related foreign currency derivatives                           326.4  
Deferred income taxes                     (141.8)     (16.4) (53.8)
Amortization of financing fees and debt discount (premium)                     0.0     0.0 0.0
Other non-cash adjustments                     17.5     17.0 10.5
Subtotal                     477.5     1,051.0 758.3
Increase (decrease) in cash due to:                              
Accounts receivable                     86.1     (81.7) (226.7)
Inventories                     (70.0)     10.7 83.0
Accounts payable                     (199.5)     140.6 (24.9)
Payroll and related taxes                     (38.2)     (30.2) (55.5)
Accrued customer programs                     27.0     69.9 113.1
Accrued liabilities                     75.6     37.3 23.0
Accrued income taxes                     (30.5)     17.5 (10.7)
Other                     (4.8)     (16.8) 33.9
Subtotal                     (154.3)     147.3 (64.8)
Net cash from (for) operating activities                     323.2     1,198.3 693.5
Cash Flows From (For) Investing Activities                              
Proceeds from royalty rights                     0.0     0.0 0.0
Acquisitions of businesses, net of cash acquired                     (791.6)     (2,177.8) (1,605.8)
Asset acquisitions                           (4.0)  
Settlement of acquisition-related foreign currency derivatives                           (329.9)  
Proceeds from sale of securities                             81.4
Additions to property and equipment                     (77.8)     (137.0) (171.6)
Other investing                     (5.0)     1.8 (8.8)
Net cash from (for) investing activities                     (874.4)     (2,646.9) (1,704.8)
Cash Flows From (For) Financing Activities                              
Issuances of long-term debt                           2,504.3 3,293.6
Borrowings (repayments) of revolving credit agreements and other financing, net                     762.0     (52.5) (3.0)
Payments on long-term debt                     (28.3)     (1,823.5) (2,035.0)
Deferred financing fees                     (0.3)     (28.1) (48.8)
Premium on early debt retirement                             (133.5)
Equity issuance costs                           (35.7)  
Issuance of ordinary shares                     4.9     1,043.4 9.8
Repurchase of ordinary shares                     (500.0)        
Cash dividends                     (36.3)     (64.8) (46.1)
Purchase of noncontrolling interest                           0.0  
Other financing                     (8.4)     (19.2) (9.0)
Net cash from (for) financing activities                     193.6     1,523.9 1,028.0
Effect of exchange rate changes on cash and cash equivalents                     (10.2)     (89.2) 2.9
Net increase (decrease) in cash and cash equivalents                     (367.8)     (13.9) 19.6
Cash and cash equivalents, beginning of period       417.8   785.6       799.5 785.6 799.5 417.8 799.5 779.9
Cash and cash equivalents, end of period         417.8   785.6       417.8     785.6 799.5
Adjustments | Tysabri®                              
Cash Flows From (For) Operating Activities                              
Net income                     30.6     26.3 28.6
Adjustments to derive cash flows                              
Total loss on extinguishment of debt                     0.0     0.0 0.0
Restructuring charges                     0.0     0.0 0.0
Depreciation and amortization                     (145.0)     (290.1) (152.8)
Impairment charges (credits)                     0.0     0.0 0.0
Tysabri® royalty stream - change in fair value                     (57.3)     (78.5) (26.6)
Share-based compensation                     0.0     0.0 0.0
Loss on acquisition-related foreign currency derivatives                           0.0  
Deferred income taxes                     4.4     3.8 4.1
Amortization of financing fees and debt discount (premium)                     0.0     0.0 0.0
Other non-cash adjustments                     0.0     0.0 0.0
Subtotal                     (167.3)     (338.5) (146.7)
Increase (decrease) in cash due to:                              
Accounts receivable                     2.6     (4.3) 86.2
Inventories                     0.0     0.0 0.0
Accounts payable                     0.0     0.0 0.0
Payroll and related taxes                     0.0     0.0 0.0
Accrued customer programs                     0.0     0.0 0.0
Accrued liabilities                     0.0     0.0 0.0
Accrued income taxes                     0.0     0.0 0.0
Other                     0.0     0.0 0.0
Subtotal                     2.6     (4.3) 86.2
Net cash from (for) operating activities                     (164.7)     (342.8) (60.5)
Cash Flows From (For) Investing Activities                              
Proceeds from royalty rights                     164.7     342.8 60.5
Acquisitions of businesses, net of cash acquired                     0.0     0.0 0.0
Asset acquisitions                           0.0  
Settlement of acquisition-related foreign currency derivatives                           0.0  
Proceeds from sale of securities                             0.0
Additions to property and equipment                     0.0     0.0 0.0
Other investing                     0.0     0.0 0.0
Net cash from (for) investing activities                     164.7     342.8 60.5
Cash Flows From (For) Financing Activities                              
Issuances of long-term debt                           0.0 0.0
Borrowings (repayments) of revolving credit agreements and other financing, net                     0.0     0.0 0.0
Payments on long-term debt                     0.0     0.0  
Deferred financing fees                     0.0     0.0 0.0
Premium on early debt retirement                             0.0
Equity issuance costs                           0.0  
Issuance of ordinary shares                     0.0     0.0 0.0
Repurchase of ordinary shares                     0.0        
Cash dividends                     0.0     0.0 0.0
Purchase of noncontrolling interest                           0.0  
Other financing                     0.0     0.0 0.0
Net cash from (for) financing activities                     0.0     0.0 0.0
Effect of exchange rate changes on cash and cash equivalents                     0.0     0.0 0.0
Net increase (decrease) in cash and cash equivalents                     0.0     0.0 0.0
Cash and cash equivalents, beginning of period       0.0   0.0       0.0 0.0 0.0 0.0 0.0 0.0
Cash and cash equivalents, end of period         0.0   0.0       0.0     0.0 0.0
Adjustments | Other                              
Cash Flows From (For) Operating Activities                              
Net income                     6.3     (18.2) (1.1)
Adjustments to derive cash flows                              
Total loss on extinguishment of debt                     0.0     0.0 0.0
Restructuring charges                     0.0     0.0 0.0
Depreciation and amortization                     (0.6)     0.0 0.0
Impairment charges (credits)                     0.0     6.8 6.0
Tysabri® royalty stream - change in fair value                     0.0     0.0 0.0
Share-based compensation                     (2.0)     0.0 0.0
Loss on acquisition-related foreign currency derivatives                           0.0  
Deferred income taxes                     17.4     (3.7) 0.0
Amortization of financing fees and debt discount (premium)                     (10.2)     0.2 2.0
Other non-cash adjustments                     0.6     (6.8) (6.0)
Subtotal                     11.5     (21.7) 0.9
Increase (decrease) in cash due to:                              
Accounts receivable                     (36.2)     34.9 0.0
Inventories                     40.4     (22.1) 1.7
Accounts payable                     5.4     (20.1) 0.0
Payroll and related taxes                     0.0     0.0 0.0
Accrued customer programs                     7.4     1.4 0.0
Accrued liabilities                     32.5     5.5 0.0
Accrued income taxes                     (26.3)     4.4 (0.6)
Other                     7.7     17.4 (2.0)
Subtotal                     30.9     21.4 (0.9)
Net cash from (for) operating activities                     42.4     (0.3) 0.0
Cash Flows From (For) Investing Activities                              
Proceeds from royalty rights                     1.6     1.8 0.0
Acquisitions of businesses, net of cash acquired                     0.0     0.0 0.0
Asset acquisitions                           0.0  
Settlement of acquisition-related foreign currency derivatives                           0.0  
Proceeds from sale of securities                             0.0
Additions to property and equipment                     0.0     0.0 0.0
Other investing                     1.3     0.0 0.0
Net cash from (for) investing activities                     1.6     1.8 0.0
Cash Flows From (For) Financing Activities                              
Issuances of long-term debt                           0.0 0.0
Borrowings (repayments) of revolving credit agreements and other financing, net                     (44.0)     (1.5) 0.0
Payments on long-term debt                     0.0     0.0 0.0
Deferred financing fees                     0.0     0.0 0.0
Premium on early debt retirement                             0.0
Equity issuance costs                           0.0  
Issuance of ordinary shares                     0.0     0.1 0.0
Repurchase of ordinary shares                     0.0        
Cash dividends                     0.0     0.0 0.0
Purchase of noncontrolling interest                           0.0  
Other financing                     0.0     (0.1) 0.0
Net cash from (for) financing activities                     (44.0)     (1.5) 0.0
Effect of exchange rate changes on cash and cash equivalents                     0.0     0.0 0.0
Net increase (decrease) in cash and cash equivalents                     0.0     0.0 0.0
Cash and cash equivalents, beginning of period       $ 0.0   $ 0.0       $ 0.0 0.0 $ 0.0 $ 0.0 0.0 0.0
Cash and cash equivalents, end of period         $ 0.0   $ 0.0       $ 0.0     $ 0.0 $ 0.0
[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9
[2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million.
[3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million.
[4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million.
[5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million.
[6] Includes Mylan defense-related fees of $15.6 million.
[7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees.
[8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million.
[9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million.